128 related articles for article (PubMed ID: 35293739)
21. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
22. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
[TBL] [Abstract][Full Text] [Related]
23. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
24. A synthetic bivalent ligand of CXCR4 inhibits HIV infection.
Xu Y; Duggineni S; Espitia S; Richman DD; An J; Huang Z
Biochem Biophys Res Commun; 2013 Jun; 435(4):646-50. PubMed ID: 23688427
[TBL] [Abstract][Full Text] [Related]
25. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.
Choi WT; Kumar S; Madani N; Han X; Tian S; Dong CZ; Liu D; Duggineni S; Yuan J; Sodroski JG; Huang Z; An J
Biochemistry; 2012 Sep; 51(36):7078-86. PubMed ID: 22897429
[TBL] [Abstract][Full Text] [Related]
26. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines.
Zhou N; Luo Z; Luo J; Fan X; Cayabyab M; Hiraoka M; Liu D; Han X; Pesavento J; Dong CZ; Wang Y; An J; Kaji H; Sodroski JG; Huang Z
J Biol Chem; 2002 May; 277(20):17476-85. PubMed ID: 11880384
[TBL] [Abstract][Full Text] [Related]
27. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory role of CXCR4 glycan in CD4-independent X4-tropic human immunodeficiency virus type 1 infection and its abrogation in CD4-dependent infection.
Kubo Y; Yokoyama M; Yoshii H; Mitani C; Tominaga C; Tanaka Y; Sato H; Yamamoto N
J Gen Virol; 2007 Nov; 88(Pt 11):3139-3144. PubMed ID: 17947541
[TBL] [Abstract][Full Text] [Related]
29. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.
BouHamdan M; Strayer DS; Wei D; Mukhtar M; Duan LX; Hoxie J; Pomerantz RJ
Gene Ther; 2001 Mar; 8(5):408-18. PubMed ID: 11313818
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
32. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
Huang W; Eshleman SH; Toma J; Fransen S; Stawiski E; Paxinos EE; Whitcomb JM; Young AM; Donnell D; Mmiro F; Musoke P; Guay LA; Jackson JB; Parkin NT; Petropoulos CJ
J Virol; 2007 Aug; 81(15):7885-93. PubMed ID: 17507467
[TBL] [Abstract][Full Text] [Related]
33. Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus.
Aiuti A; Turchetto L; Cota M; Cipponi A; Brambilla A; Arcelloni C; Paroni R; Vicenzi E; Bordignon C; Poli G
Blood; 1999 Jul; 94(1):62-73. PubMed ID: 10381499
[TBL] [Abstract][Full Text] [Related]
34. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.
Jenkinson S; Thomson M; McCoy D; Edelstein M; Danehower S; Lawrence W; Wheelan P; Spaltenstein A; Gudmundsson K
Antimicrob Agents Chemother; 2010 Feb; 54(2):817-24. PubMed ID: 19949058
[TBL] [Abstract][Full Text] [Related]
35. Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.
Wilkinson RA; Pincus SH; Shepard JB; Walton SK; Bergin EP; Labib M; Teintze M
Antimicrob Agents Chemother; 2011 Jan; 55(1):255-63. PubMed ID: 20937786
[TBL] [Abstract][Full Text] [Related]
36. Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions.
Wang J; He L; Combs CA; Roderiquez G; Norcross MA
Mol Cancer Ther; 2006 Oct; 5(10):2474-83. PubMed ID: 17041091
[TBL] [Abstract][Full Text] [Related]
37. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
38. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus.
Ghosn J; Bayan T; Meixenberger K; Tran L; Frange P; d'Arminio Monforte A; Zangerle R; de Mendoza C; Krastinova E; Porter K; Meyer L; Chaix ML;
J Antimicrob Chemother; 2017 Oct; 72(10):2862-2868. PubMed ID: 29091208
[TBL] [Abstract][Full Text] [Related]
39. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
40. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
